Latest Breaking News On - Prior treatment - Page 1 : comparemela.com

Gilead Sciences, Inc : Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA

- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:

United statesFoster cityCarol ohearFrank neumannJacquie rossBrexucabtagene autoleucelPivekimab sunirineAxicabtagene ciloleucelCressida robsonMeaghan smithDecitabine cedazuridineSanta monicaGlobal head of clinical developmentGilead sciencesGilead sciences incClinical development

Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA

– Eight Presentations on Yescarta® and Tecartus® Advance Kite’s Cell Therapy Leadership – – New Data Highlight Magrolimab’s Potential to Alter the Tumor. | June 1, 2023

Foster cityUnited statesDecitabine cedazuridineSanta monicaCarol ohearFrank neumannPivekimab sunirineAxicabtagene ciloleucelBrexucabtagene autoleucelDrug administrationExchange commissionGilead companyEuropean hematology associationClinical developmentGilead sciences incGilead sciences

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023

– Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Hematologic, Genitourinary, Gastrointestinal, Gynecological and. | May 17, 2023

Foster cityUnited statesDomvanalimab domPembrolizumab pembroEtrumadenant etrumaAxicabtagene ciloleucelZimberelimab zimFrank neumannSanta monicaBrexucabtagene autoleucel brexuGilead sciencesDrug administrationGilead sciences incGilead companyAmerican society of clinical oncologyKite global head of clinical development

More than 35 Abstracts from Incyte s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition

Numerous oral presentations highlighting data for tafasitamab, parsaclisib, ruxolitinib, pemigatinib, itacitinib and ponatinib to be highlighted during the Congress Incyte (Nasdaq:INCY) today announced

United statesUnited kingdomCatalina lovemanPeter langmuirPonatinib iclusigTafasitamab lenalidomideChristine chiouAmerican society of hematology annual meetingXencor incGroup viceDrug administrationHealth services researchOutcomes researchTakeda pharmaceutical companyMillennium pharmaceuticals incExchange commission

Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases

Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

New south walesUnited statesApril armstrongJoe zhuoJanin edelkampMelinda gooderhamRichard warrenJenny xieMary beth harlerRichardb warrenFarah toublanNeil kormanAnjaneya chimalakondaBristol myers squibbJashinj wuJosephf merola